Organogenesis Sells Trauma Business to Acellixx
Ticker: ORGO · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1661181
| Field | Detail |
|---|---|
| Company | Organogenesis Holdings INC. (ORGO) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, business-sale
TL;DR
Organogenesis is selling its Trauma business to Acellixx to focus on its main regenerative medicine products.
AI Summary
Organogenesis Holdings Inc. announced on April 3, 2024, that it has entered into a definitive agreement to sell its Trauma business to Acellixx, Inc. for an undisclosed amount. This strategic divestiture is expected to allow Organogenesis to focus on its core regenerative medicine business.
Why It Matters
This divestiture signals a strategic shift for Organogenesis, allowing it to concentrate resources on its core regenerative medicine offerings and potentially improve financial performance.
Risk Assessment
Risk Level: medium — The sale of a business segment can introduce execution risks and uncertainty regarding the future financial performance and strategic direction of the remaining company.
Key Players & Entities
- Organogenesis Holdings Inc. (company) — Registrant
- Acellixx, Inc. (company) — Buyer of Trauma business
- April 3, 2024 (date) — Date of agreement
FAQ
What is the financial value of the sale of the Trauma business to Acellixx, Inc.?
The filing states that Organogenesis Holdings Inc. has entered into a definitive agreement to sell its Trauma business to Acellixx, Inc., but the specific dollar amount of the transaction is not disclosed in this 8-K filing.
When was the agreement to sell the Trauma business finalized?
The agreement to sell the Trauma business was announced on April 3, 2024.
What is the primary reason for Organogenesis Holdings Inc. selling its Trauma business?
The filing indicates that the divestiture is a strategic move to allow Organogenesis to focus on its core regenerative medicine business.
What specific business segment is Organogenesis Holdings Inc. selling?
Organogenesis Holdings Inc. is selling its Trauma business.
What is the acquiring company's name?
The acquiring company's name is Acellixx, Inc.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-03 17:26:02
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value ORGO Nasdaq Capital Marke
Filing Documents
- d822694d8k.htm (8-K) — 24KB
- d822694dex991.htm (EX-99.1) — 3KB
- g822694g0404015729548.jpg (GRAPHIC) — 5KB
- 0001193125-24-086129.txt ( ) — 151KB
- orgo-20240403.xsd (EX-101.SCH) — 3KB
- orgo-20240403_lab.xml (EX-101.LAB) — 17KB
- orgo-20240403_pre.xml (EX-101.PRE) — 11KB
- d822694d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated April 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Organogenesis Holdings Inc. By: /s/ Lori Freedman Name: Lori Freedman Title: Chief Administrative and Legal Officer Date: April 3, 2024